在帕金森病中进行远程Levodopa挑战测试:可行性,可靠性,有效性和经济价值
Zhitong Zeng1, Zhengyu Lin1, Zhonglue Chen2
1Department of Neurosurgery, Centre for Functional Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
European journal of neurology
|August 8, 2024
概括
对于帕金森病 (PD) 患者来说,在家中进行远程Levodopa挑战测试 (LCT) 是可行的,可靠的和有效的. 这种远程LCT显著降低了PD患者的医疗费用.
科学领域:
- 神经学 神经学
- 数字健康数字健康
- 临床试验 临床试验
背景情况:
- 帕金森病 (PD) 管理需要对利沃多巴反应进行准确的评估.
- 传统的医院内检测对PD患者 (PwPD) 提出了后勤和财务上的挑战.
- 远程,技术支持的医疗保健解决方案对于慢性疾病管理越来越重要.
研究的目的:
- 为了确定PwPD的家庭远程Levodopa挑战测试 (LCT) 的可行性,可靠性和有效性.
- 通过在线平台评估通过在线平台提供的远程LCT的性能.
- 评估与远程LCT相关的潜在成本节约.
主要方法:
- 采用了一种序列性,比较性研究设计,将家庭远程LCT与PwPD的医院标准LCT进行比较.
- 参与者接受了两种测试方法,大约隔三周.
- 使用修改后的运动障碍学会统一帕金森病评级尺度第三部分评估了勒沃多巴反应,可靠性和有效性分别通过类内相关性和皮尔森相关系数来确定.
主要成果:
- 在106名接受查的PwPD中,有80人 (75.5%) 成功完成了远程和标准LCT协议.
- 与标准LCT相比,远程LCT表现出良好的可靠性 (类内相关系数=0.81) 和强大的并发有效性 (r=0.84).
- 估计PwPD使用远程LCT的平均成本降低是相当大的,为91%.
结论:
- 在家中进行远程Levodopa挑战测试 (LCT) 是一种可行,可靠和有效的方法,用于评估帕金森病患者的Levodopa反应.
- 这种远程方法为PwPD及其护理人员提供了减少医疗保健相关费用的巨大潜力.
- 这些发现支持将数字健康工具整合到帕金森病常规护理中.
相关概念视频
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508


